<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613662</url>
  </required_header>
  <id_info>
    <org_study_id>SP-102-03</org_study_id>
    <nct_id>NCT03613662</nct_id>
  </id_info>
  <brief_title>A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102</brief_title>
  <official_title>An Open-label, Single-arm Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects With Lumbosacral Radiculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semnur Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scilex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scilex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, repeat dose study to characterize the pharmacodynamics and
      safety/tolerability of SP-102 administered by epidural injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Actual">March 15, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma cortisol in mcg/dL</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of white blood cell counts in 10^3/mcL</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood glucose in mg/dL</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Lumbosacral Radicular Pain</condition>
  <arm_group>
    <arm_group_label>SP-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SP-102</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-102</intervention_name>
    <description>Injection</description>
    <arm_group_label>SP-102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Able and willing to read, write, and understand the English language and provide
             English language written informed consent prior to beginning any study procedures.

          -  Age 18 to 70 years (inclusive) at the Screening Visit.

          -  A diagnosis of lumbosacral radicular pain (sciatica).

          -  Agrees to follow study-specific medication requirements.

          -  If sexually active and a female of child-bearing potential or a male capable of
             bearing a child, agrees to use an effective method of birth control during the study.

          -  Has reviewed all study specific materials and has, in the opinion of the Investigator,
             the abilities to understand and appropriately complete all study procedures.

        Main Exclusion Criteria:

          -  Has radiologic evidence of a condition that would compromise study outcomes.

          -  Has ever had lumbosacral back surgery or plans to undergo spine surgical intervention
             while in the study.

          -  Has been diagnosed with insulin dependent diabetes mellitus.

          -  Presence of any other disorder, condition or circumstance (including secondary gain)
             that, in the opinion of the Investigator, has the potential to prevent study
             completion and/or to have a confounding effect on outcome assessments.

          -  Use of any investigational drug and/or device within 30 days, or is scheduled to
             receive an investigational drug other than blinded study drug during this study.

          -  Has a body mass index â‰¥40 kg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitri Lissin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Semnur Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Semnur Research Site 1</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lumbosacral radicular pain</keyword>
  <keyword>sciatica</keyword>
  <keyword>leg pain</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

